HHS says Gilead, distributor can directly sell COVID-19 drug in U.S.
Reuters
Published Oct 01, 2020 02:26PM ET
(Reuters) - The U.S. Department of Health and Human Services (HHS) said on Thursday that U.S. hospitals can now buy Gilead Sciences Inc (NASDAQ:GILD)'s antiviral COVID-19 drug remdesivir from the company and its distributor.
The drug, branded as Veklury, was being distributed across the United States by HHS.
Gilead said it is now meeting real-time demand for remdesivir in the U.S. and anticipates meeting global demand for the drug in October, even in the event of potential future surges of COVID-19.
Gilead donated courses of the drug after it was authorized in May for use in patients with a severe form of COVID-19. Trial data showed the antiviral drug helped shorten hospital recovery time.
AmerisourceBergen (NYSE:ABC) will continue to serve as the sole U.S. distributor of remdesivir through the end of this year and will sell the product directly to hospitals, Gilead said.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.